Additional file 8: Figure S6. of BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells Amy Campbell Jonathan Oliva Matthew Yates Jun Zhong Sean Shadle Lauren Snider Nikita Singh Shannon Tai Yosuke Hiramuki Rabi Tawil Silvère Maarel Stephen Tapscott Francis Sverdrup 10.6084/m9.figshare.c.3870838_D11.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_8_Figure_S6_of_BET_bromodomain_inhibitors_and_agonists_of_the_beta-2_adrenergic_receptor_identified_in_screens_for_compounds_that_inhibit_DUX4_expression_in_FSHD_muscle_cells/5374558 Characterization of BET gene expression. (A-C) 54-2 FSHD1 and 54-6 control (non-FSHD, Normal) myoblasts were induced to differentiate into myotubes and gene expression measured. Differentiation efficiency was determined by examining the early differentiation marker MYOG and the late differentiation marker MYH2 (A). As expected, DUX4 targets were strongly induced upon differentiation of FSHD1 but not control myoblasts (B). The levels of BET family member (BRD2, BRD3, BRD4, BRDT) mRNAs are shown in (C). (D) Tracks showing ChIP-seq and RNA-seq reads mapped to the BRDT locus in DUX4-expressing muscle cells. Error bars indicate the standard deviation from the mean of three biological replicates. (PDF 117 kb) 2017-09-04 05:00:00 Facioscapulohumeral muscular dystrophy FSHD DUX4 Bromodomain Adrenergic High-throughput screening